Universitätsklinikum Ulm

The German National Registry of Primary Immunodeficiencies (2012-2017) (2019) El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, et al. Journal article Impact of social support on psychosocial symptoms and quality of life in cancer patients: results of a multilevel model approach from a longitudinal multicenter study (2019) Sauer C, Weis J, Faller H, Junne F, Honig K, Bergelt C, Hornemann B, et al. Journal article Lung injury after asphyxia and hemorrhagic shock in newborn piglets: Analysis of structural and inflammatory changes (2019) Weber B, Mendler MR, Lackner I, Von Zelewski A, Hoefler S, Baur M, Braun CK, et al. Journal article Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study (2019) Wallwiener M, Nabieva N, Feisst M, Fehm T, De Waal J, Rezai M, Baier B, et al. Journal article IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation (2019) Hotter D, Bosso M, Jønsson KL, Krapp C, Stürzel CM, Das A, Littwitz-Salomon E, et al. Journal article Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide (2019) Potthoff AL, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, Güresir Á, et al. Journal article High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer (2019) Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, et al. Journal article Dasatinib reduces myelofibrosis by modulating pSTAT5 and NF-κB (2019) Schelker RC, Andrulis M, Mueller G, Ushmorov A, Hart C, Herr W, Vogelhuber M, et al. Journal article Preservation of Microvascular Integrity in Murine Orthotopic Tracheal Allografts by Clopidogrel (2019) Heim C, Khan MA, von Silva-Tarouca B, Kuckhahn A, Stamminger T, Ramsperger-Gleixner M, Nicolls MR, et al. Journal article Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) Saraceni F, Labopin M, Brecht A, Kroeger N, Eder M, Tischer J, Labussiere-Wallet H, et al. Journal article